The Russian peptide research tradition

The lineage

Several peptides discussed across this site share a common origin: the Russian (and earlier Soviet) bioregulator research tradition. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology developed the framework of "tissue-specific bioregulator peptides" that produced Pinealon, Cortagen, Vesugen, Bonothyrk, and Cardiogen, plus the better-known Epitalon. Nikolai Myasoedov's group at the Russian Academy of Sciences developed Semax (an ACTH-fragment peptide) and Selank (a tuftsin-derived anxiolytic). Ever Pharma in Austria developed Cerebrolysin, which was widely adopted in the Russian and broader Eastern European clinical practice.

This is a real research lineage with real publications, real clinical practice, and real preclinical literature. It's worth understanding rather than dismissing.

What the tradition does well

• Long-term clinical follow-up. The Khavinson group's mortality studies in elderly cohorts span multi-decade follow-up that few Western longevity studies match.
• Multi-system biology. The Russian framework has consistently emphasized peptides as regulatory rather than purely receptor-binding agents — a perspective that aligns with recent Western interest in mitokines, gasotransmitters, and other broad signaling molecules.
• Practical clinical use. Cerebrolysin has been used in stroke and TBI care in 50+ countries; Semax has been used in stroke recovery in Russia for decades. Clinical experience volume is substantial.

What deserves calibration

• Within-group concentration. The Khavinson group accounts for the majority of positive findings on Khavinson short peptides. The Sikiric group (BPC-157) and other research traditions show similar concentration patterns. Independent replication is the field's gold standard, and concentration in originating groups should be flagged in evidence reading.
• Methodological heterogeneity. Trial designs, blinding, statistical handling, and reporting standards across the Russian-language literature vary considerably. Some studies meet modern Western standards; others don't.
• Translation and access. A meaningful portion of the Russian literature isn't translated, isn't indexed in Western databases, or appears in journals that aren't indexed at all. This complicates evidence-grading at scale and means Western reviews can miss real findings or include only the studies that happened to be translated.
• Mechanistic claims. Some Russian frameworks — particularly the proposed direct DNA / nuclear interactions of short peptides in the Khavinson framework — have not been widely established outside the originating research lineage.

Where the field is converging

Some of the tradition's findings have entered Western mainstream interest through different channels. The discovery of mitochondrial-derived peptides (MOTS-c, humanin) in Western labs reproduced a "peptides as broad regulatory signaling" framework that the Russian tradition had been working with for decades. Cerebrolysin's CARS and CAPTAIN clinical programs have brought its data into the Western evidence ecosystem, with Cochrane reviews flagging both promising signals and methodological concerns.

The emerging picture is that the dismissive treatment of Russian peptide research in some Western coverage is too strong, while the uncritical adoption in some biohacker communities is also too strong. The middle reading — that the lineage has produced real findings, that some are reproducible and some are not, and that careful work is needed to sort which is which — is more useful than either pole.

What we'd want to see

A meaningful step forward would be independent Western RCTs of the better-supported Russian-tradition peptides — particularly the Khavinson mortality findings in elderly populations, which are extraordinary if reproducible. Replication is the question, not whether the findings exist.